Cyxone recruits key members to the clinical development team

Cyxone today announced that the company has recruited Anna Polak and Levente Dajka as members of the Cyxone development team. Both will bring vast knowledge in clinical trial management, their initial focus will fall primarily on the preparations for the planned phase 2 trial investigating the clinical effect of Rabeximod in rheumatoid arthritis, set to start during 2021.

Anna Polak holds a degree in pharmacy from the Medical University of Warsaw and has 15 years of global trial management experience in contract research organizations (CROs), ranging from initial protocol design to final clinical document transfer. She has experience from organizing global multi-site studies, the largest one taking place in 24 countries at 200 research sites, including eleven phase 2 studies in rare diseases and immunological indications such as rheumatoid arthritis.

Levente Dajka has 20 years of experience from preclinical and clinical pharmaceutical development as well as post-market surveillance research, following drug market approval. He holds a degree in biology from the University of Pécs, Hungary. Levente Dajka has previously worked in therapeutic development projects in the pharmaceutical industry and CROs, managing global clinical trial teams in the U.S., EU and Asia targeting multiple sclerosis and rheumatoid arthritis as well as oncological, gastroenterological and other immunological indications.

“I am delighted to welcome both Anna Polak and Levente Dajka to Cyxone as new members of our development team. They both bring a vast amount of experience from all stages of clinical drug development on a global scale. Their background in immunological diseases in general, and in multiple sclerosis and rheumatoid arthritis specifically, will be of great value as we increase our activities in preparing a regulatory submission to initiate the planned clinical phase 2 study in RA”, says Tara Heitner, CEO of Cyxone AB.

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com